| |
| |
|
| Insider
Information: |
Haluska Frank |
| Relationship: |
SVP, Clinical R&D, CMO |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
147,011 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
147,011 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ariad Pharmaceuticals Inc |
ARIA |
SVP, Clinical R&D, CMO |
2016-03-21 |
147,011 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
49 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 2
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARIA |
Ariad Pharmaceuticals Inc |
VP, Clinical R&D, CMOOfficer |
• – – |
2010-06-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,931 |
|
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
VP, Clinical R&D, CMO |
• – – |
2011-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,334 |
28,265 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
VP, Clinical R&D, CMO |
• – – |
2011-03-22 |
4 |
D |
$6.39 |
$28,116 |
D/D |
(4,400) |
23,865 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-02-21 |
4 |
OE |
$2.39 |
$10,755 |
D/D |
4,500 |
28,365 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-02-21 |
4 |
AS |
$14.51 |
$65,277 |
D/D |
(4,500) |
23,865 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
30,000 |
53,865 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-20 |
4 |
S |
$15.02 |
$225,240 |
D/D |
(15,000) |
38,865 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,333 |
52,198 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-23 |
4 |
AS |
$15.41 |
$102,718 |
D/D |
(6,667) |
45,531 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-26 |
4 |
OE |
$2.39 |
$7,170 |
D/D |
3,000 |
48,531 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-03-26 |
4 |
AS |
$16.00 |
$48,000 |
D/D |
(3,000) |
45,531 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
54,031 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• – – |
2012-04-03 |
4 |
AS |
$16.18 |
$68,767 |
D/D |
(4,250) |
49,781 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2012-12-18 |
4 |
D |
$20.18 |
$107,438 |
D/D |
(5,324) |
57,207 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2012-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
62,531 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,000 |
63,207 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$46,694 |
D/D |
(2,400) |
60,807 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,333 |
74,140 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-03-25 |
4 |
S |
$18.88 |
$100,672 |
D/D |
(5,333) |
68,807 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,500 |
77,307 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-04-02 |
4 |
S |
$18.04 |
$61,339 |
D/D |
(3,400) |
73,907 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-07-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,000 |
89,907 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-07-18 |
4 |
AS |
$19.79 |
$126,642 |
D/D |
(6,400) |
83,507 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-12-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,750 |
96,257 |
0 |
- |
|
| ARIA |
Ariad Pharmaceuticals Inc |
SVP, Clinical R&D, CMO |
• • – |
2013-12-19 |
4 |
AS |
$5.14 |
$26,214 |
D/D |
(5,100) |
91,157 |
0 |
- |
|
49 Records found
|
|
Page 1 of 2 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
